Intracranial Hemorrhage clinical trials at UCSF
4 research studies open to eligible people
An intracranial hemorrhage is when bleeding occurs within the brain. UCSF is testing if apixaban works better than aspirin to prevent strokes after a brain hemorrhage. Researchers are also exploring early use of recombinant Factor VIIa to treat acute strokes. Another study investigates genetics in babies with seizures to learn more about epilepsy.
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
open to eligible people ages 18 years and up
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
San Francisco, California and other locations
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
open to eligible people ages 18-80
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy.
San Francisco, California and other locations
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
open to eligible people ages 18-80
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include only those treated within 2 hours with a positive spot sign on a baseline CT angiogram.
San Francisco, California and other locations
Neonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy
open to all eligible people
The NSR-GENE study is a longitudinal cohort study of approximately 300 parent-child trios from the Neonatal Seizure Registry and participating site outpatient clinics that aims to evaluate whether and how genes alter the risk of post-neonatal epilepsy among children with acute provoked neonatal seizures. The researchers aim to develop prediction rules to stratify neonates into low, medium, and high risk for post-neonatal epilepsy based on clinical, electroencephalogram (EEG), magnetic resonance imaging (MRI), and genetic risk factors.
San Francisco, California and other locations
Our lead scientists for Intracranial Hemorrhage research studies include Hannah C Glass, MDCM, MAS.
Last updated: